A5018745115- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Immunodeficiency and Autoimmune Disorders
- Blood Coagulation and Thrombosis Mechanisms
- Cancer Immunotherapy and Biomarkers
- Chronic Kidney Disease and Diabetes
- Acute Myeloid Leukemia Research
- Acute Kidney Injury Research
- Asthma and respiratory diseases
- Herbal Medicine Research Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Blood Pressure and Hypertension Studies
- Cell death mechanisms and regulation
- Trace Elements in Health
- Organ Transplantation Techniques and Outcomes
- Pancreatic and Hepatic Oncology Research
- Apelin-related biomedical research
- Neurogenetic and Muscular Disorders Research
- Identification and Quantification in Food
- Dermatology and Skin Diseases
- Neuroblastoma Research and Treatments
- Urticaria and Related Conditions
- Diabetes Treatment and Management
- Melanoma and MAPK Pathways
Renji Hospital
2025
Shanghai Cancer Institute
2025
Fudan University
2025
Shanghai Jiao Tong University
2025
University of Hong Kong
2020-2024
Queen Mary Hospital
2020-2024
Nanjing Medical University
2016-2023
Kyoto University
2023
Chinese University of Hong Kong
2022-2023
Jiangsu Province Blood Center
2021-2022
Hemophagocytic lymphohistiocytosis (HLH) can be classified into primary HLH and secondary HLH. Primary usually occurs in infants children with an underlying genetic defect, there are also teens occasional adults Most cases adult patients triggers including infections, malignancies, autoimmune diseases. The distinction between seems to less straightforward, as may have defects while triggered by causes. In this study, using amplicon-based targeted gene sequencing (TGS), we sequenced eighteen...
Ibrutinib, a first-generation Bruton's tyrosine kinase (BTK) inhibitor, could improve immunity of relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphoma (CLL/SLL) patients. Whether zanubrutinib, second-generation selective BTK has similar effects as ibrutinib remains to be determined. Dynamics number and immunophenotype immune cells during zanubrutinib treatment in 25 R/R CLL/SLL patients were examined by flow cytometry blood routine tests. The expression intensity...
Background Incidence and mortality rates of pancreatic cancer have either remained stable or increased slightly in many countries. The 5-year relative survival rate for is the lowest among 25 common cancers. This study focuses on situation, variations trends worldwide. Methods comprehensive overview searched 6 databases (PubMed, Web Science, EMBASE, SEER, CNKI SinoMed) all articles published before January 1st, 2024. Survival estimates from final included literature were extracted compared....
Abstract Protease-activated receptor (PAR)-1 has emerged as a key profibrotic player in various organs including kidney. PAR-1 activation leads to deposition of extracellular matrix (ECM) proteins the tubulointerstitium and induction epithelial–mesenchymal transition (EMT) during renal fibrosis. We tested anti-fibrotic potential vorapaxar, clinically approved antagonist for cardiovascular protection, an experimental kidney fibrosis model unilateral ureteral obstruction (UUO) AKI-to-chronic...
Chronic lymphocytic leukemia (CLL) is one of the most frequent type B-cell chronic lymphoproliferative disorders and inflammation takes part in development CLL. However, there has been no valid immune biomarker to predict prognosis untreated CLL patients.In this retrospective study, we analyzed clinical correlations prognostic value albumin-to-fibrinogen ratio (AFR) detected at diagnosis 191 patients.The cut-off AFR was 9.7 calculated by X-tile. Patients who were more than 65 years old often...
Background: Previous retrospective cohorts showed that Rehmannia-6 (R-6, Liu-wei-di-huang-wan) formulations were associated with significant kidney function preservation and mortality reduction among chronic disease patients diabetes. This study aimed to investigate the potential mechanism of action common R-6 variations in a clinical protocol for diabetic nephropathy (DN) from system pharmacology approach. Study Design Methods: Disease-related genes retrieved GeneCards OMIM by searching...
Background: Splicing factor 3b subunit 1 (SF3B1), a splicing modulating RNA alternative splicing, is frequently mutated in multiple hematological malignancies including myelodysplastic syndromes and chronic lymphocytic leukemia (CLL). The clinical impact of SF3B1 mutation on CLL remains controversial especially for patients Asian descent. Methods: We retrospectively analyzed the frequency by Sanger sequencing 399 newly diagnosed Chinese patients. Results: was detected 5.5% (22/399) studied...
Abstract The proto‐oncogene NOTCH 1 is frequently mutated in around 10% of patients with chronic lymphocytic leukemia ( CLL ). This study analyzed mutation status 317 Chinese by Sanger sequencing. frequencies the PEST (proline (P), glutamic acid (E), serine (S), threonine (T)‐rich protein sequence) domain and 3′ untranslated regions UTR ) were 8.2% 0.9%, most frequent being c.7541_7542del CT c.*371A>G, respectively. Clinical biological associations determined including mutations advanced...
Objective: To validate the prognostic value of chronic lymphocytic leukemia-international index (CLL-IPI) for Chinese CLL patients. Methods: Two hundred and fifteen patients who were initially diagnosed treated in Jiangsu Province Hospital from January 2002 to November 2017 included retrospective analysis. Risk stratification prognosis evaluated by CLL-IPI scoring system. Results: ①Of 215 patients, 143 males 72 females, with a median age 60 (16-85) years old. The treatment-free survival...
ABSTRACT Background Thromboembolic events are prevalent in chronic kidney disease (CKD) patients due to increased thrombin generation leading a hypercoagulable state. We previously demonstrated that inhibition of protease-activated receptor-1 (PAR-1) by vorapaxar reduces fibrosis. Methods used an animal model unilateral ischemia–reperfusion injury-induced CKD explore the tubulovascular crosstalk mechanisms PAR-1 acute injury (AKI)-to-CKD transition. Results During early phase AKI,...
Objective: We explore the candidate susceptibility genes for influenza A virus (IAV), measles, rubella, and mumps their underlying biological mechanisms. Methods: downloaded genome-wide association study summary data of four virus-specific immunoglobulin G (IgG) level sets (anti-IAV IgG, anti-measles anti-rubella anti-mumps IgG levels) integrated them with reference models three potential tissues from Genotype-Tissue Expression (GTEx) project, namely, whole blood, lung, transformed...
Abstract Background: NOTCH1 mutation is an essential molecular biologic aberration in chronic lymphocytic leukemia (CLL). CLL patients with have shown unfavorable survival and a poor response to chemoimmunotherapy. This study aims present the mechanisms of adverse prognosis caused by from perspective splicing factor heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1). Methods: The microarray data Gene Expression Omnibus datasets were analyzed bioinformatics function hnRNPA1 was checked...
The 11q deletion (del(11q)) is a conventional cytogenetic aberration observed in chronic lymphocytic leukemia (CLL) patients. However, the prevalence and prognostic value of del(11q) are still controversial. In this research, we retrospectively explored prevalence, association, significance 352 untreated 99 relapsed/refractory Chinese CLL Totally 11.4% 19.2% patients harbored del(11q). Del(11q) was more common with β2-microglobulin > 3.5 mg/L, positive CD38, zeta-chain associated protein...
To investigate the prognosis prediction value of PET/CT in DLBCL patients treated with CAR-T therapy.The effects were retrospectively explored on 13 R/R who therapy. Parameters reflecting tumor metabolic burden, such as volume (MTV) and total lesion glycolysis (TLG) measured before after treatment.Patients larger baseline MTV or longer sum longest diameters showed shorter overall survival (OS) time than those low burden. Patients achieved complete remission (CR), partial (PR) minor (MR)...
Extranodal natural killer/T-cell lymphoma (NKTCL), nasal type mostly involves the upper aerodigestive tract (UAT). NKTCLs derived from UAT are referred to as NKTCLs, while those without involvement extra-nasal NKTCLs. In this study, we aimed investigate outcomes and survival trends of different anatomical sites.Data US Surveillance, Epidemiology, End Results (SEER) database on NKTCL (diagnosed between 1987 2016) were retrospectively analyzed.A total 714 patients with included. The median...
As a novel immune therapy for cancer, chimeric antigen receptor T-cell (CAR-T) immunotherapy has attracted more and attention. Toxicities of CAR-T include cytokine release syndrome (CRS), neurologic toxicities on-target, off-tumor toxicity. CRS, which is the most severe adverse event immunotherapy, affects many organs, such as cardiovascular, nervous, digestive, hematological systems, so on. Besides symptomatic treatment, tocilizumab (anti-interleukin monoclonal 6 antibody), etanercept...
Introduction: Chimeric antigen receptor T cell (CAR-T) therapy is an effective treatment for relapsed or refractory (r/r) diffuse large B lymphoma (DLBCL) patients. Positron emission tomography/computed tomography (PET-CT) played important role in DLBCL the era of chemoimmunotherapy, while its value CAR-T remained undetermined. Methods: In this study, we retrospectively explored PET-CT 13 r/r patients who were receiving therapy. Parameters reflecting tumor metabolic burden, such as volume...
Ibrutinib, a first-generation Bruton's tyrosine kinase (BTK) inhibitor, could improve immunity of relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphoma (CLL/SLL) patients. Whether zanubrutinib, second-generation BTK has similar effects as ibrutinib remains to be determined. Dynamics number and immunophenotype immune cells during zanubrutinib treatment in 25 R/R CLL/SLL patients were examined by flow cytometry blood routine tests. The expression intensity programmed cell...
Chimeric antigen receptor-T cell (CAR-T) therapy is one of the effective novel immunotherapy for malignancies, and it has a great effect on leukemia lymphoma. More researches are needed to improve understanding CAR-T promote development this technology in order treat hematological malignancies from perspective. Key words: Chimeric receptor T-cell; Immunotherapy; Hematologic neoplasms; American Society Hematology annual meeting